retatrutide latest clinical trial results Lilly orforglipron oral GLP-1 phase 3 weight loss Lilly's retatrutide delivers promising results

Resmetirom received FDA approval for the fibrotic stage, but the steatosis stage, where the vast majority of patients sit, has no approved pharmacological intervention

These findings might lay the foundation for the potential regenerative treatment of patients with chronic stroke

As of the TRIUMPH-4 readout, the answer is yes

Participants receiving retatrutide lost an average of 11.5% and as much as 16.8% of their body weight after 40 weeks, far exceeding the placebo groups 2.6% reduction

Key Benefits: This combination peptide therapy gives your body a gentle, effective nudge to naturally produce more growth hormonewithout harsh side effects

Here, we highlight the mechanisms linking T2DM and PD, as well as the links between insulin resistance (IR) and PD patients risk of developing cognitive deficits